Kol A Zarember

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Innate immunity against Granulibacter bethesdensis, an emerging gram-negative bacterial pathogen
    Kol A Zarember
    Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Infect Immun 80:975-81. 2012
  2. pmc Antifungal activities of natural and synthetic iron chelators alone and in combination with azole and polyene antibiotics against Aspergillus fumigatus
    Kol A Zarember
    Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 1456, USA
    Antimicrob Agents Chemother 53:2654-6. 2009
  3. pmc Role of laeA in the Regulation of alb1, gliP, Conidial Morphology, and Virulence in Aspergillus fumigatus
    Janyce A Sugui
    Laboratory of Clinical Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Eukaryot Cell 6:1552-61. 2007
  4. pmc Tryptophan/kynurenine metabolism in human leukocytes is independent of superoxide and is fully maintained in chronic granulomatous disease
    Suk See De Ravin
    Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 116:1755-60. 2010
  5. pmc Genes differentially expressed in conidia and hyphae of Aspergillus fumigatus upon exposure to human neutrophils
    Janyce A Sugui
    Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 3:e2655. 2008
  6. pmc Serologic reactivity to the emerging pathogen Granulibacter bethesdensis
    David E Greenberg
    Laboratory of Clinical Infectious Diseases, Bethesda, MD, USA
    J Infect Dis 206:943-51. 2012
  7. pmc Recurrent Granulibacter bethesdensis infections and chronic granulomatous disease
    David E Greenberg
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 1684, USA
    Emerg Infect Dis 16:1341-8. 2010
  8. pmc Gliotoxin is a virulence factor of Aspergillus fumigatus: gliP deletion attenuates virulence in mice immunosuppressed with hydrocortisone
    Janyce A Sugui
    Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA
    Eukaryot Cell 6:1562-9. 2007
  9. pmc Residual NADPH oxidase and survival in chronic granulomatous disease
    Douglas B Kuhns
    Clinical Services Program, SAIC Frederick, Frederick, Maryland, USA
    N Engl J Med 363:2600-10. 2010
  10. pmc B-cell activating factor (BAFF) is elevated in chronic granulomatous disease
    Kabir Matharu
    Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    Clin Immunol 148:258-64. 2013

Collaborators

Detail Information

Publications19

  1. pmc Innate immunity against Granulibacter bethesdensis, an emerging gram-negative bacterial pathogen
    Kol A Zarember
    Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Infect Immun 80:975-81. 2012
    ..bethesdensis inhibited both constitutive and FAS-induced PMN apoptosis. These properties of reduced PMN activation and resistance to nonoxidative killing mechanisms likely play an important role in G. bethesdensis pathogenesis...
  2. pmc Antifungal activities of natural and synthetic iron chelators alone and in combination with azole and polyene antibiotics against Aspergillus fumigatus
    Kol A Zarember
    Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 1456, USA
    Antimicrob Agents Chemother 53:2654-6. 2009
    ..Iron chelation alone or combined with antifungal drugs may be useful for prevention and treatment of mycosis...
  3. pmc Role of laeA in the Regulation of alb1, gliP, Conidial Morphology, and Virulence in Aspergillus fumigatus
    Janyce A Sugui
    Laboratory of Clinical Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Eukaryot Cell 6:1552-61. 2007
    ..Our results suggest that while laeA is not involved in the regulation of alb1 function in conidial morphology, it regulates the synthesis of gliotoxin and the virulence of A. fumigatus...
  4. pmc Tryptophan/kynurenine metabolism in human leukocytes is independent of superoxide and is fully maintained in chronic granulomatous disease
    Suk See De Ravin
    Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 116:1755-60. 2010
    ....
  5. pmc Genes differentially expressed in conidia and hyphae of Aspergillus fumigatus upon exposure to human neutrophils
    Janyce A Sugui
    Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 3:e2655. 2008
    ..fumigatus in response to neutrophils from healthy donors as well as from those with chronic granulomatous disease (CGD) which are defective in the production of reactive oxygen species...
  6. pmc Serologic reactivity to the emerging pathogen Granulibacter bethesdensis
    David E Greenberg
    Laboratory of Clinical Infectious Diseases, Bethesda, MD, USA
    J Infect Dis 206:943-51. 2012
    ..Its pathogenesis, environmental reservoir(s), and incidence of infection among CGD patients and the general population are unknown...
  7. pmc Recurrent Granulibacter bethesdensis infections and chronic granulomatous disease
    David E Greenberg
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 1684, USA
    Emerg Infect Dis 16:1341-8. 2010
    ..This organism is multidrug resistant, and therapy required surgery and combination antimicrobial drugs, including long-term ceftriaxone. G. bethesdensis causes necrotizing lymphadenitis in CGD, which may recur or relapse...
  8. pmc Gliotoxin is a virulence factor of Aspergillus fumigatus: gliP deletion attenuates virulence in mice immunosuppressed with hydrocortisone
    Janyce A Sugui
    Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA
    Eukaryot Cell 6:1562-9. 2007
    ..Our study confirms that gliotoxin is an important virulence determinant of A. fumigatus and that the type of immunosuppression regimen used is important to reveal the pathogenic potential of gliotoxin...
  9. pmc Residual NADPH oxidase and survival in chronic granulomatous disease
    Douglas B Kuhns
    Clinical Services Program, SAIC Frederick, Frederick, Maryland, USA
    N Engl J Med 363:2600-10. 2010
    ..We hypothesized that residual ROI production might be linked to survival in patients with chronic granulomatous disease...
  10. pmc B-cell activating factor (BAFF) is elevated in chronic granulomatous disease
    Kabir Matharu
    Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    Clin Immunol 148:258-64. 2013
    ..47) and increased rapidly in healthy subjects following intravenous endotoxin administration. These findings suggest that elevated BAFF in CGD subjects and healthy donors is a consequence of acute and chronic inflammation...
  11. doi request reprint Intermediate phenotypes in patients with autosomal dominant hyper-IgE syndrome caused by somatic mosaicism
    Amy P Hsu
    Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    J Allergy Clin Immunol 131:1586-93. 2013
    ..Autosomal dominant hyper-IgE syndrome (AD-HIES) is caused by mutations in signal transducer and activator of transcription 3 (STAT3). We describe 2 subjects in whom somatic mosaicism was associated with intermediate phenotypes...
  12. pmc Antisense phosphorodiamidate morpholino oligomers targeted to an essential gene inhibit Burkholderia cepacia complex
    David E Greenberg
    Immunopathogenesis Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, Office of Research Services, National Institutes of Health, Bethesda, Maryland, USA
    J Infect Dis 201:1822-30. 2010
    ..Many Bcc strains are antibiotic resistant, which requires the exploration of novel antimicrobial approaches, including antisense technologies such as phosphorodiamidate morpholino oligomers (PMOs)...
  13. pmc Short stature in partially corrected X-linked severe combined immunodeficiency--suboptimal response to growth hormone
    Suk See De Ravin
    Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases NIAID, Bethesda, MD 20892, USA
    J Pediatr Endocrinol Metab 21:1057-63. 2008
    ..Previous reports have implicated gamma c in growth hormone (GH) receptor signaling, thus severe growth failure in XSCID may be related to the underlying gamma c defect...
  14. pmc Persistence of the Bacterial Pathogen Granulibacter bethesdensis in Chronic Granulomatous Disease Monocytes and Macrophages Lacking a Functional NADPH Oxidase
    Jessica Chu
    Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892
    J Immunol 191:3297-307. 2013
    ....
  15. ncbi request reprint Human polymorphonuclear leukocytes inhibit Aspergillus fumigatus conidial growth by lactoferrin-mediated iron depletion
    Kol A Zarember
    Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 178:6367-73. 2007
    ..These results demonstrate that PMN lactoferrin sequestration of iron is important for host defense against Aspergillus...
  16. pmc Chronic granulomatous disease: overview and hematopoietic stem cell transplantation
    Elizabeth M Kang
    Laboratory of Host Defenses, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    J Allergy Clin Immunol 127:1319-26; quiz 1327-8. 2011
    ..We will then discuss the status of bone marrow transplantation...
  17. pmc Hypomorphic Rag mutations can cause destructive midline granulomatous disease
    Suk See De Ravin
    Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 116:1263-71. 2010
    ..This study was registered at www.clinicaltrials.gov as #NCT00128973...
  18. pmc Impaired priming and activation of the neutrophil NADPH oxidase in patients with IRAK4 or NEMO deficiency
    Anjali Singh
    Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 1504, USA
    J Immunol 182:6410-7. 2009
    ..Decreased activation of NOX may contribute to the increased risk of infection seen in patients with IRAK4 and NEMO deficiency...
  19. pmc HIF-1alpha: a master regulator of innate host defenses?
    Kol A Zarember
    Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Clin Invest 115:1702-4. 2005
    ..identify a novel and essential role for hypoxia-inducible factor-1alpha in regulating several important PMN functions relevant to host defense, including transcription of cationic antimicrobial polypeptides and induction of NO synthase...